Last reviewed · How we verify
Aqueous Suppressant Eye Drops
At a glance
| Generic name | Aqueous Suppressant Eye Drops |
|---|---|
| Also known as | Timoptic, Trusopt, Azopt, Alphagan-P, Xalatan |
| Sponsor | Credit Valley EyeCare |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy (NA)
- Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves (PHASE4)
- Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aqueous Suppressant Eye Drops CI brief — competitive landscape report
- Aqueous Suppressant Eye Drops updates RSS · CI watch RSS
- Credit Valley EyeCare portfolio CI